Incyte Corporation (INCY)

Last Price: 83.25 (2020-11-27)

Company Description

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $2.16B
Net Income (Most Recent Fiscal Year) $446.91M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 7.24
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 7.43
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 32.43
Pre-Tax Margin (Trailing 12 Months) -11.17%
Net Margin (Trailing 12 Months) -13.62%
Return on Equity (Trailing 12 Months) -13.66%
Return on Assets (Trailing 12 Months) -9.98%
Current Ratio (Most Recent Fiscal Quarter) 3.56
Quick Ratio (Most Recent Fiscal Quarter) 3.53
Debt to Common Equity (Most Recent Fiscal Quarter) 0.01
Inventory Turnover (Trailing 12 Months) 8.67
Book Value per Share (Most Recent Fiscal Quarter) $10.92
Earnings per Share (Most Recent Fiscal Quarter) $0.03
Earnings per Share (Most Recent Fiscal Year) $2.23
Diluted Earnings per Share (Trailing 12 Months) $-1.57
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 219.00M
Free Float 183.74M
Market Capitalization $17.77B
Average Volume (Last 20 Days) 1.27M
Beta (Past 60 Months) 1.08
Percentage Held By Insiders (Latest Annual Proxy Report) 16.10%
Percentage Held By Institutions (Latest 13F Reports) 84.69%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%